Nrf2 overexpression promotes cancer progression and drug resistance in various cancers by activating several oncogenes such as matrix metallopeptidase 9, B-cell lymphoma 2, tumour necrosis factor α, and vascular endothelial growth factor A80–82. This evidence concerns the gene MMP9 and cancer.